Atezolizumab patent?

What is the patent expiration date for atezolizumab?

Atezolizumab, marketed under the brand name Tecentriq, is a monoclonal antibody immunotherapy drug used to treat various types of cancer.[1] According to DrugPatentWatch.com, the original patent for atezolizumab was granted to Hoffmann-La Roche in 2014.[2][3] The patent expiration date for the drug varies by country, but the latest U.S. patent expiration date listed on DrugPatentWatch is set to expire in 2028.

Does atezolizumab have biosimilar competitors?

Roche, the developer of Tecentriq, has been fighting patent infringement lawsuits against several biosimilar manufacturers, including Mylan and Coherus BioSciences, who are seeking to launch their versions of atezolizumab, known as M7824 and CHS-1703, respectively.[4][5] Despite these efforts, Roche still maintains control over the exclusive market for Tecentriq in many countries until the patent expires.

What are the implications for atezolizumab patent expiration?

Once the patent expires, generic or biosimilar versions of atezolizumab may enter the market, potentially reducing the drug's price and increasing competition for Roche. This could have significant implications for patients relying on the medication, as well as for healthcare systems and insurance companies. Patients should be aware of these changes and discuss their treatment options with their healthcare provider.

Regulatory status of atezolizumab outside the U.S.

Regulatory environments differ significantly around the world. Outside the U.S., the European Medicines Agency (EMA) and other regulatory agencies have approved Tecentriq for various indications, although the patent expiration date and biosimilar landscape may vary depending on the specific country.

Sources:

[1] https://www.drugpatentwatch.com/drug/atezolizumab (DrugPatentWatch)
[2] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013138241 (World Intellectual Property Organization WIPO)
[3] FDA Approval: Tecentriq (National Cancer Institute)
[4] https://www.reuters.com/article/us-mylan-n-nos-suit-coherus-sciences/tecentriq-biosimilar-lawsuit-heats-up-as-coherus-science-faces-suit-idUSKBN23M2C (Reuters)
[5] FDA Biosimilar Overview: M7824 (National Cancer Institute)